Literature DB >> 10594572

Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Y M Van Der Geld1, P C Limburg, C G Kallenberg.   

Abstract

Anti-neutrophil cytoplasmic antibodies directed against PR3 (PR3-ANCA) in patients with Wegener's granulomatosis are supposedly involved in the pathophysiology of this disease as different functional characteristics of the autoantibodies correlate with disease activity. However, little is known about the epitopes of PR3 that are recognized by PR3-ANCA and how epitope specificity may relate to functional characteristics of PR3-ANCA. As candidate tools for epitope mapping we studied 13 anti-PR3 MoAbs, including nine widely used and four newly raised MoAbs, for their mutual binding characteristics to PR3 using biosensor technology. Antigen specificity was confirmed by indirect immunofluorescence, immunoblotting, FACS analysis and antigen-specific ELISA. Competition between anti-PR3 MoAbs in binding to PR3 was investigated in a capture system set up in a BIAcore. In this system grouping of 12 of the 13 anti-PR3 MoAbs based on their mutual recognition patterns was achieved. Four MoAbs, from different research groups, namely 12.8, PR3G-2, 6A6 and Hz1F12, recognized comparable epitopes (group 1). Group 2 MoAbs including PR3G-4 and PR3G-6 bound to overlapping regions on PR3. The MoAbs PR3G-3, 4A5 and WGM2 recognized similar epitopes as they inhibited binding of each other (group 3). The fourth group of related MoAbs consisted of MC-PR3-2, 4A3 and WGM3. Because of its binding characteristics MoAb WGM1 could not be grouped. These results demonstrate that eight well-established anti-PR3 MoAbs produced by different research groups and four newly produced anti-PR3 MoAbs recognize four separate epitope areas on PR3, including one area detected with newly raised MoAbs only.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594572      PMCID: PMC1905445          DOI: 10.1046/j.1365-2249.1999.01079.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

2.  Towards standard sera for the determination of anti-neutrophil cytoplasmic (ANCA) and anti-myeloperoxidase (aMPO) antibodies.

Authors:  C G Kallenberg; J W Tervaert; M G Huitema; M van der Giessen
Journal:  APMIS Suppl       Date:  1989

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters.

Authors:  R C Kao; N G Wehner; K M Skubitz; B H Gray; J R Hoidal
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.

Authors:  J L Niles; R T McCluskey; M F Ahmad; M A Arnaout
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

6.  Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen.

Authors:  J Lüdemann; B Utecht; W L Gross
Journal:  J Immunol Methods       Date:  1988-11-10       Impact factor: 2.303

7.  Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes.

Authors:  J Sun; D N Fass; J A Hudson; M A Viss; J Wieslander; H A Homburger; U Specks
Journal:  J Immunol Methods       Date:  1998-02-01       Impact factor: 2.303

8.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

9.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation.

Authors:  N Borregaard; J M Heiple; E R Simons; R A Clark
Journal:  J Cell Biol       Date:  1983-07       Impact factor: 10.539

View more
  15 in total

Review 1.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 3.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Current methods for detecting antibodies against erythropoietin and other recombinant proteins.

Authors:  Robin Thorpe; Steven J Swanson
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

5.  Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.

Authors:  Francisco Silva; Amber M Hummel; Dieter E Jenne; Ulrich Specks
Journal:  J Autoimmun       Date:  2010-12       Impact factor: 7.094

6.  MCF-7 mammary tumour cells express the myeloid cell differentiation controlling factor, serine protease 3/myeloblastin.

Authors:  S Horman; D Fokan; P Galand
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

7.  Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen.

Authors:  Katrin S Reiners; Hinrich P Hansen; Anne Krüssmann; Gisela Schön; Elena Csernok; Wolfgang L Gross; Andreas Engert; Elke Pogge Von Strandmann
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

8.  Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing.

Authors:  S von Vietinghoff; C Eulenberg; M Wellner; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2008-06       Impact factor: 4.330

9.  Standardised assessment of membrane proteinase 3 expression. Analysis in ANCA-associated vasculitis and controls.

Authors:  André P van Rossum; Minke G Huitema; Coen A Stegeman; Marc Bijl; Karina de Leeuw; Miek A Van Leeuwen; Pieter C Limburg; Cees G M Kallenberg
Journal:  Ann Rheum Dis       Date:  2007-04-19       Impact factor: 19.103

10.  Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.

Authors:  Agnieszka A Rarok; Ymke M van der Geld; Coen A Stegeman; Pieter C Limburg; Cees G M Kallenberg
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.